The estimated Net Worth of Israel Ben Yoram is at least $1.01 Milion dollars as of 8 April 2019. Israel Yoram owns over 71,429 units of Pluri Inc stock worth over $387,235 and over the last 17 years Israel sold PSTI stock worth over $618,356.
Israel has made over 12 trades of the Pluri Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Israel bought 71,429 units of PSTI stock worth $50,000 on 8 April 2019.
The largest trade Israel's ever made was buying 71,429 units of Pluri Inc stock on 8 April 2019 worth over $50,000. On average, Israel trades about 12,474 units every 131 days since 2007. As of 8 April 2019 Israel still owns at least 387,235 units of Pluri Inc stock.
You can see the complete history of Israel Yoram stock trades at the bottom of the page.
Israel's mailing address filed with the SEC is 24 BARKAN STREET, , RISHON LEZION, L3, 75436.
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman a Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Pluri Inc executives and other stock owners filed with the SEC include: